contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-fluoguide-as-nasdaq-fluo-live-webcast-on-25-february-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

FluoGuide is a Danish company operating in the medical technology sector. The company's business focus is on research and development of treatments for various forms of cancer, with the greatest focus on the development of products that guide surgical procedures. The products bind to cancer cells, which then light up and are intended to be used to precisely remove harmful tumors in the patient's tissue.

FluoGuide

FluoGuide A/S will publish its Annual Report 2025 on Wednesday, 25 February 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen will present the company’s 2025 financial results, ...

<div class="mfn-preamble"><p><strong>FluoGuide A/S will publish its Annual Report 2025 on Wednesday, 25 February 2026.</strong></p></div><div class="mfn-body"><p>Later that day, CEO Morten Albrechtsen and CFO Ole Larsen will present the company’s 2025 financial results, strategic progress and expectations for 2026 in a live webcast. The webcast is hosted by BioStock.&nbsp;The presentation will be followed by a live Q&amp;A session, where questions can be asked during the event or submitted in advance by e-mail to <a rel="noopener" href="mailto:redaktion@biostock.se">redaktion@biostock.se</a>.</p><p><strong>Date: Wednesday 25 February 2026</strong><strong><br></strong><strong>Time: 14.00 CET</strong></p><p>Please login to the webcast via the following link: <a rel="noopener" href="https://www.youtube.com/live/DlK74aNE86M">https://www.youtube.com/live/DlK74aNE86M</a><br>Questions can be sent in advance by email to redaktion@biostock.se or can be raised at the question session during the webcast.<br>A recorded version of the presentation will be available on FluoGuide’s website after the webcast.<br>&nbsp;</p></div><div class="mfn-footer mfn-contacts mfn-c60fb25dd154"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Morten Albrechtsen, CEO<br>FluoGuide A/S<br>Phone: +45 24 25 62 66<br>E-mail: ma@fluoguide.com</p></div><div class="mfn-footer mfn-7804fb3d90e5"><p><strong class="mfn-heading-1">Certified Adviser:</strong><br>Svensk Kapitalmarknadsgranskning AB<br>Website: www.skmg.se</p></div><div class="mfn-footer mfn-67044b16f1f8"><p><strong class="mfn-heading-1">Follow FluoGuide on linkedIn</strong><br>Follow FluoGuide on LinkedIn: <a rel="noopener" href="https://www.linkedin.com/company/fluoguide/">https://www.linkedin.com/company/fluoguide/</a></p></div><div class="mfn-footer mfn-4fc4c77ad72e"><p><strong class="mfn-heading-1">Sign up to receive FluoGuide news</strong><br>Sign up to receive FluoGuide news: <a rel="noopener" href="https://fluoguide.com/investor/email-alerts/">https://fluoguide.com/investor/email-alerts/</a></p></div><div class="mfn-footer mfn-about mfn-889f859209e1"><p><strong class="mfn-heading-1">About FluoGuide</strong><br>FluoGuide lights up cancer to maximize surgical outcomes in oncology. FluoGuide’s lead product, FG001, is designed to improve surgical precision by lighting up cancer intraoperatively. The improved precision has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision enhances the likelihood of complete cure and lower healthcare costs. FluoGuide has demonstrated that FG001 is both effective and well tolerated in several phase II clinical trials. The lead indications of FG001 are aggressive brain cancer (glioblastoma) and oral head and neck cancer. FluoGuide has entered partnerships with leading MedTech companies with the aim of accelerating development and commercialization. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.</p><p>For more information on FG001 or FluoGuide’s uPAR technology platform, please visit our home page www.fluoguide.com</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/eec41676-a3eb-4cc4-a727-0ca9057cd0fb/invitation-to-fluoguide-a-s-nasdaq-fluo-live-webcast-on-25-february-2026.pdf" class="mfn-generated mfn-primary">Invitation to FluoGuide A/S (Nasdaq: FLUO) live webcast on 25 February 2026</a></p></div>